SNP (np. MTHFR) Screening: information you need

SNP (np. MTHFR) Screening helps you understand common single-nucleotide polymorphisms in the MTHFR gene, how they can influence methylation and health, what diagnostic tests detect, which risk factors matter, and how clinicians interpret results to guide lifestyle, supplementation, or further testing.

Interpretation Results for SNP (eg. MTHFR)

Interpreting SNP results for genes like MTHFR involves assessing genotype (wild-type, heterozygous, homozygous) to estimate relative enzyme activity and potential impact on folate-dependent methylation; clinicians integrate genotype with biochemical markers (plasma homocysteine, serum folate, RBC folate, B12) and clinical context (symptoms, medications, pregnancy, thrombotic history) to determine whether lifestyle changes, targeted dietary folate/B12 forms (methylfolate, methylcobalamin), or further testing are warranted; isolated heterozygosity often has minimal clinical effect, homozygosity for common variants may modestly raise homocysteine and merit monitoring or supplementation, and any management should prioritize objective labs and risk factors rather than genotype alone.

How to Interpret a SNP?

Interpreting a SNP starts with identifying the genotype (wild-type, heterozygous, homozygous) to estimate likely functional effect, then integrating that genetic result with biochemical markers (plasma homocysteine, serum/RBC folate, B12) and the clinical context (symptoms, medications, pregnancy, thrombotic history) to decide if intervention is needed; isolated heterozygosity is often clinically insignificant, homozygosity for common MTHFR variants can modestly reduce enzyme activity and raise homocysteine so may prompt monitoring and targeted supplementation (methylfolate, methylcobalamin) or lifestyle changes, but management should be guided by objective labs and risk factors rather than genotype alone and may warrant further testing if labs or clinical history indicate elevated risk.

Indications for SNP Testing (e.g. MTHFR)

Consider SNP testing (e.g., MTHFR) when clinical or laboratory findings suggest altered folate/methylation physiology—unexplained elevated homocysteine, recurrent pregnancy loss or infertility, history of thrombosis, unexplained neuropsychiatric symptoms or developmental concerns, poor response to standard folate/B12 therapy, strong family history of related disorders, or when medications/clinical situations (pregnancy, IVF, chronic disease) raise concern; use testing as an adjunct to, not a replacement for, biochemical assessment (homocysteine, serum/RBC folate, B12) and clinical risk factors, since isolated heterozygosity is often clinically insignificant while homozygosity or concordant risk factors may justify monitoring, targeted supplementation (methylfolate/methylcobalamin), or further workup.

Analyzing SNP

Analyzing SNPs (e.g., MTHFR) begins by identifying genotype (wild-type, heterozygous, homozygous) to estimate likely functional impact, then integrating that result with biochemical markers (plasma homocysteine, serum/RBC folate, B12) and clinical context (symptoms, medications, pregnancy, thrombotic or reproductive history) to judge clinical relevance; isolated heterozygosity is often of minimal consequence, whereas homozygosity for common variants can modestly reduce enzyme activity and raise homocysteine, potentially prompting monitoring, targeted supplementation (methylfolate, methylcobalamin) or lifestyle changes. Consider SNP testing when laboratory or clinical clues suggest altered folate/methylation physiology—unexplained hyperhomocysteinemia, recurrent pregnancy loss or infertility, thrombosis history, neurodevelopmental or neuropsychiatric concerns, poor response to standard folate/B12 therapy, strong family history, or medication/pregnancy-related risks—and use genetic results as an adjunct to, not a replacement for, objective biochemical assessment and overall risk-factor–based management.

SNP Testing (e.g. MTHFR): Indications, Preparation, Procedure & Potential Side Effects

Consider SNP testing (e.g., MTHFR) when clinical or laboratory clues suggest altered folate/methylation physiology—unexplained elevated homocysteine, recurrent pregnancy loss or infertility, thrombotic history, unexplained neurodevelopmental or psychiatric symptoms, poor response to standard folate/B12 therapy, strong family history, or medication/pregnancy-related risks; testing is an adjunct to, not a replacement for, biochemical assessment (plasma homocysteine, serum/RBC folate, B12) and clinical evaluation. Preparation is minimal: provide informed consent, avoid changing supplements or medications that affect B12/folate for a short period if instructed, and ensure relevant biochemical tests are done concurrently or beforehand. Procedure is noninvasive—buccal swab or blood sample is collected and sent to a lab for genotyping, with results reported as wild-type, heterozygous, or homozygous and interpreted alongside labs and clinical context. Potential side effects are rare and limited to local discomfort from phlebotomy or swabbing; psychological or insurance/privacy concerns may occur, so discuss implications, data handling, and counseling options before testing.

The MTHFR gene test was once routinely ordered as part of workups for blood clots, recurrent pregnancy loss, and unexplained cardiovascular disease. That practice has now been formally pushed back on by the American College of Medical Genetics and Genomics (ACMG), which concluded that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of a routine evaluation for thrombophilia. MedlinePlus echoes this plainly: medical experts do not recommend testing for common MTHFR gene changes in most cases.

The historical rationale was a chain of assumptions: reduced MTHFR enzyme activity raises blood homocysteine, and elevated homocysteine drives clots and heart disease. Subsequent meta-analyses have disproven the link between hyperhomocysteinemia and coronary heart disease, and they have disproven the link between MTHFR polymorphism status and venous thromboembolism. The original mechanism does not hold up at the population level.

There are also practical reasons the test is rarely useful:

The treatment for high homocysteine is the same whether or not the cause is an MTHFR variant.
Researchers are not certain that high homocysteine itself directly causes blood clots or heart disease, so identifying a genetic contributor does not change the management plan.
The two common variants tested (C677T and A1298C) are extremely common in the general population — more US adults carry at least one copy of C677T than do not. A finding shared by most of the population cannot, on its own, explain an individual case.

Insurance coverage often follows the guidance: many plans decline to pay for MTHFR genotyping because professional bodies recommend against it. The takeaway is not that the test is harmful, but that it almost never changes what a clinician would do next.

What MTHFR variants actually do (and don’t do)

The MTHFR gene provides instructions for making the MTHFR protein, which helps your body process folate — a B vitamin needed to make DNA and modify proteins. When the protein works less efficiently, less folate is converted into its active form, and the amino acid homocysteine is broken down more slowly. That can show up as a modestly higher homocysteine level on a blood test.

The two common variants — C677T and A1298C — are not diseases. They are normal human genetic variation. The CDC describes gene variants as “common and normal” and notes that more people in the United States carry at least one copy of C677T than do not. The C677T variant is more common in Hispanic individuals than in non-Hispanic White or non-Hispanic Black individuals.

What the variants do not cause

Online content often attributes specific symptoms or chronic conditions to MTHFR variants. The cached evidence does not support most of these claims:

There is no symptom checklist. People who carry C677T or A1298C usually have no symptoms attributable to the variant itself. The variants are too common in the general population to function as a meaningful disease label.
Folic acid is not “toxic” for people with MTHFR variants. The CDC states explicitly that people with an MTHFR gene variant can process all types of folate, including folic acid.
The variants do not, on their own, prove a cause for clots, heart attacks, miscarriages, or psychiatric conditions. The disproven hyperhomocysteinemia chain cuts off the most common claimed mechanism.

A separate, much rarer condition called homocystinuria is caused by severe MTHFR deficiency and does cause illness from infancy. It is detected by a different test — most US newborns are screened shortly after birth — and is not what the common adult MTHFR genotype test is designed to find.

How to interpret your results

Results from an MTHFR gene test are reported as positive or negative for the C677T and A1298C variants. A positive result means you carry one or both of the common changes; a negative result means neither was found.

A positive result by itself rarely changes what a clinician will do. The clinical interpretation depends on whether your homocysteine is also elevated and on which combination of variants you carry.

Reference summary for interpreting a positive result with elevated homocysteine:

Genotype combination	Likely contribution to elevated homocysteine
Two copies of C677T (homozygous)	Probably contributing
One copy each of C677T and A1298C (compound heterozygous)	Probably contributing
Two copies of A1298C (homozygous)	Probably not the cause
One copy only of either variant (heterozygous)	Unlikely to cause health problems

If your test is negative but your homocysteine is high, the elevation is probably from another cause. MedlinePlus lists several: a lack of B vitamins, certain medications, older age, hypothyroidism, kidney disease, or another underlying condition. The next step is usually to investigate those alternatives rather than to repeat the genetic test. A check of vitamin B12 and folate levels, plus thyroid and kidney function, is often more informative than the genotype itself.

The treatment for elevated homocysteine is broadly the same regardless of MTHFR status: B-vitamin repletion, with the specific form chosen by the prescribing clinician. Methylated folate (5-MTHF) is sometimes recommended for people with a variant on the theory that it bypasses the MTHFR step, but folic acid itself is also processed normally.

MTHFR, homocysteine, and the cardiovascular question

Much of the historical interest in MTHFR testing came from the homocysteine hypothesis: the idea that higher blood homocysteine, driven in part by reduced MTHFR enzyme activity, would raise the risk of heart attacks, strokes, and venous clots. Some studies showed that high homocysteine can damage the inside of blood vessels, which suggested a plausible biological link.

The evidence has not held up. The ACMG Practice Guideline summarizes the more recent data: meta-analyses have disproven the association between hyperhomocysteinemia and coronary heart disease and disproven the link between MTHFR polymorphism status and venous thromboembolism. MedlinePlus puts the current uncertainty more cautiously: researchers are not certain that increased homocysteine levels directly cause health problems, and on that basis some experts recommend against using MTHFR testing for cardiovascular risk assessment.

Practical implications

If you have already had the test and it is positive, the result does not raise your individual cardiovascular risk in a way that warrants new medication or genotype-driven treatment.
If you have a personal or family history of early heart or vessel disease, the appropriate workup focuses on validated cardiovascular risk factors (lipids, blood pressure, diabetes, smoking, family history) rather than on MTHFR genotype.
If your homocysteine is high, the management — usually B-vitamin repletion — does not depend on knowing your MTHFR genotype. Tracking the homocysteine level itself is the more actionable measurement.

MTHFR in pregnancy: what the evidence actually says

Pregnancy is the area where MTHFR myths cause the most confusion, because folate genuinely matters in early pregnancy. Higher homocysteine during pregnancy can increase the risk of a baby with neural tube defects, early pregnancy loss, and preeclampsia. That makes folate adequacy a real clinical concern.

The intervention, however, is not MTHFR testing — it is folic acid intake. The CDC’s guidance is direct: anyone who could become pregnant should get 400 micrograms of folic acid daily, even if they have an MTHFR variant. MedlinePlus reinforces this: studies show that taking folic acid greatly reduces the risk of neural tube defects, and the CDC recommends folic acid supplements for everyone who may become pregnant, regardless of MTHFR status.

Why the “avoid folic acid” advice is wrong

A common online claim is that people with an MTHFR variant should avoid folic acid and take only methylated folate. The CDC addresses this directly: people with an MTHFR gene variant can process all types of folate, including folic acid, and folic acid is the only form proven to prevent neural tube defects.

When intake is adequate, the difference in blood folate by genotype is small. People with the MTHFR 677 TT genotype have an average blood folate level only about 16% lower than people with the CC genotype when both groups consume the same amount of folic acid. Folic acid intake matters more for blood folate levels than MTHFR genotype does.

For recurrent pregnancy loss, MTHFR genotype is not currently considered a strong predictor and does not change first-line counseling. The evidence-based intervention remains 400 micrograms of folic acid daily before and during early pregnancy.

When to talk to your doctor

The MTHFR test is genuinely useful in a small number of clinical situations. Outside those situations, MedlinePlus and the ACMG both discourage routine ordering. Talk to a clinician — and consider whether testing is appropriate — in scenarios such as:

A blood test has shown higher than normal homocysteine, AND a close relative has been diagnosed with an MTHFR gene change.
A blood test has shown higher than normal homocysteine, AND you or close family members have early heart or blood vessel disease.
A clinician is considering methotrexate for cancer, psoriasis, or rheumatoid arthritis. The MTHFR protein is involved in how the body processes methotrexate, and genotype results may help inform a safe dose.
A newborn screened positive for homocystinuria, in which case targeted MTHFR testing may be ordered as part of follow-up.

You should also speak with a clinician — rather than self-interpreting — if you already have an MTHFR result from a direct-to-consumer service and you are not sure what to do with it. A homocysteine level, plus a check of folate and B12 status and other contributors such as thyroid and kidney function, is usually a more informative next step than acting on the genotype alone.

If you carry a positive MTHFR result and you could become pregnant, the action item is straightforward: take 400 micrograms of folic acid daily, the same recommendation that applies to anyone who could become pregnant.

Frequently asked questions

Does 23andMe test for the MTHFR gene mutation?

Direct-to-consumer genetic services often include the C677T and A1298C variants in their raw data. A positive finding from a consumer service does not, on its own, change clinical management. Medical experts do not recommend testing for common MTHFR gene changes in most cases.

How much does an MTHFR gene test cost?

Pricing varies by lab and region, and insurance coverage is inconsistent. Many plans decline to pay for MTHFR genotyping because the ACMG Practice Guideline recommends against ordering it as a routine part of thrombophilia evaluation. Out-of-pocket pricing is common when there is no qualifying clinical indication.

Can I test for MTHFR at home?

Home genotyping kits can detect C677T and A1298C, but a result in isolation is hard to act on. Interpretation depends on a current homocysteine level and on context such as folate and B12 status, medications, age, thyroid function, and kidney function — none of which a home kit measures.

Should I avoid folic acid if I have an MTHFR variant?

No. The CDC states that people with an MTHFR gene variant can process all types of folate, including folic acid, and folic acid is the only form proven to prevent neural tube defects. Anyone who could become pregnant is advised to get 400 micrograms of folic acid daily even if they have an MTHFR variant.

What are the symptoms of an MTHFR mutation?

The common C677T and A1298C variants usually have no specific symptoms. They are common genetic variation rather than a disease — more US adults carry at least one copy of C677T than do not. The rare condition homocystinuria, caused by severe MTHFR deficiency, does cause symptoms from early life but is detected by different testing.

Is methylated folate better than folic acid if I have MTHFR?

When intake is adequate, the difference is small. People with the MTHFR 677 TT genotype have blood folate levels only about 16% lower than people with the CC genotype on the same folic acid intake. Folic acid is the only form proven to prevent neural tube defects. A clinician may suggest methylfolate (5-MTHF) in some cases, but the evidence does not establish a general advantage.

Will my insurance cover an MTHFR test?

Coverage is often denied because the ACMG Practice Guideline concluded that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of a routine thrombophilia evaluation. Coverage is more likely with a specific qualifying indication, such as elevated homocysteine with relevant family history, or methotrexate dosing decisions.

References

Last reviewed: 2026-05-17